Repurposed Ebola vaccine meets Bundibugyo surge—turning point or dead end?
A fast‑growing outbreak centered in DRC, with fatalities near half of infections, detections in Kenya and Nigeria, and security and labor threats to responders, coincides with a WHO‑backed trial of Merck’s Ervebo.
The DRC’s Bundibugyo Ebola outbreak has surpassed 10,000 confirmed cases with roughly 4,900 deaths, as authorities launch the country’s first trial of Merck’s Ervebo—approved for Zaire Ebola—to tes...